We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





World’s Only Hygienic Digital Urine Test Launched

By LabMedica International staff writers
Posted on 28 Jan 2019
The world’s only hygienic, easy-to-use and accurate digital point-of-care urine test named Urine Testing System was launched at Arab Health 2019 by Clinical Design (Penryn, Cornwall, UK). More...
The digital point-of-care urine test has been designed to improve the entire process from receiving the sample and recording results, to analysis in the laboratory.

The highly intuitive system features sealed, leak-proof samples, automatically timed readings and the ability to save digital results directly into the patient’s electronic health record. No decanting is required, reducing the risk of contamination and false positive samples being sent to laboratories. Digital readings are also more accurate compared to manual urinalysis as they eliminate variation in subjective analysis and the risk of error during manual recording.

Urine Testing System works seamlessly as a closed integrated system and includes a patented, single-use cap containing reagent pads to test ten parameters: leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketone, bilirubin and glucose. Once the patient has collected the urine sample, the healthcare professional simply connects UTS-10 Cap; creating a sealed, leak-proof module. This UTS module is then loaded into the UTS Digital Analyzer and the automatically timed, digital results are shown on the integrated LCD screen or in the UTS Desktop Software if connected to a computer.

The sample can be disposed of in clinical waste or be sent to the laboratory with no need to decant. It is specially designed to fit in standard laboratory racking – and can be purchased with or without boric acid depending on laboratory requirements. The current test takes approximately one to two minutes and risks include spillage of a contaminated sample, as well as human errors during analysis and/or the manual recording into a patient's records.

“We have developed a simple integrated system that increases the efficacy of patient point-of-care urine testing and improves first-time diagnosis. It is the only closed urine testing system available anywhere in the world and we are delighted to be able to showcase it at Arab Health 2019,” said Oliver Blackwell, CEO of Clinical Design.

Related Links:
Clinical Design

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
HPV Test
Allplex HPV28 Detection
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.